Skip to content

Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT

Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02029742
Acronym
HABIT
Enrollment
60
Registered
2014-01-08
Start date
2013-09-30
Completion date
2015-12-31
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

Sickle cell disease, Medication adherence, Hydroxyurea, Community health worker intervention, Sickle Cell Treatment

Brief summary

The investigators propose that culturally aligned community-based interventions in our multi-ethnic sickle cell disease (SCD) population, augmented by task-focused communication technology, can improve self-managed adherence to hydroxyurea (HU) by decreasing barriers to use, supporting parent-youth partnerships for chronic disease self-management and reinforcing the behavior of daily medication use. Culturally aligned community health workers (CHW) are a well-established means to support chronic disease self-management by underserved families, in partnership with medical homes. CHWs can identify and address multiple barriers and reinforce developmentally appropriate self-management to help youth reach and maintain their best fetal hemoglobin (HbF) levels. However, this strategy alone may be insufficient to achieve daily HU adherence. The investigators therefore propose a feasibility trial to test the feasibility and acceptability of a structured intervention of CHW support to address existing barriers to improve HU use, augmented by daily cue-based parent and youth text message reminders, to efficiently extend CHW family support and reinforce family partnerships for self-management.

Detailed description

Sickle cell disease (SCD) is an inherited disorder affecting the blood and causes anemia, painful sickle crises, organ damage, reduced quality of life and high health care use. Hydroxyurea (HU) is an oral medication that reduces disease symptoms and improves quality of life by increasing the amount of fetal hemoglobin in the blood. Despite the clinical promise of hydroxyurea, many children with SCD do make taking hydroxyurea a daily health habit. General barriers to medication adherence in underserved populations include lack of trust of medical staff, incomplete knowledge regarding benefits of hydroxyurea, and other factors that impede access to care such as transportation difficulties. Challenges specific to hydroxyurea use include understanding the importance of maximizing fetal hemoglobin levels and addressing concerns about hydroxyurea. Children and adolescents also require that a developmentally appropriate transition of self-management be established with their parents. Community-based health workers are a well established means to provide support for chronic disease management for underserved families and address multi-faceted barriers through culturally, behaviorally and developmentally aligned intervention. The investigators hypothesize that Community Health Workers support, augmented by daily task-focused communication technology, can improve self-managed adherence to hydroxyurea.

Interventions

CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.

BEHAVIORALEducation

Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.

Sponsors

National Institute of Nursing Research (NINR)
CollaboratorNIH
Montefiore Medical Center
CollaboratorOTHER
Columbia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Youth: 1. Sickle type - homozygous sickle disease or sickle-beta thalassemia disease 2. Age 10 to 18 years 3. Currently prescribed hydroxyurea (HU) ≥18 months (for assessing historical hydroxyurea adherence and identify personal best) 4. ≥3 fetal hemoglobin assessments over past 12 months with pre-HbF ≥10% below historical personal best value 5. Youth has/uses cell phone with text message capability 6. Youth able to speak/read English or Spanish. 7. Youth willing to participate Parent: 1. Parent/legal guardian meets all inclusion criteria 2. Parent/guardian speaks/reads English or Spanish 3. Parent/ legal guardian willing to participate 4. Family expected to reside in community for ≥ 1 years

Exclusion criteria

Youth: 1. A different sickle type 2. Youth \< 10 years of age or ≥ 18 years of age 3. Youth not prescribed hydroxyurea, or on chronic transfusions 4. \<3 fetal hemoglobin assessments over past 12 months 5. Sexually active female ≥11 not using reliable contraception (due to hydroxyurea teratogenic risk) 6. Pregnancy 7. Cognitive impairment (\>1 level below expected grade) 8. Youth not residing with parent/legal guardian 9. Sibling of a youth enrolled in this study Parent: 1. Parent/legal guardian is not the primary caregiver 2. Youth in foster care

Design outcomes

Primary

MeasureTime frameDescription
Effect size of the intervention on hydroxyurea (HU) adherence6 monthsIn this feasibility study, feasibility will be assessed of our methods, the impact of the intervention on adherence to hydroxyurea, and the ability to retain subjects throughout the 6 month period. These data will be used to calculate the effect size of the intervention to estimate the sample needed for a larger trial.

Secondary

MeasureTime frameDescription
Effect size of the intervention on youth-parent communication about self-management responsibility6 monthsThe investigators will estimate the effect size of the intervention on youth-parent communication about self-management responsibility by assessing quantitative changes in questionnaires administered to both parents and youth.
Effect size of the intervention on youth-parent communication about quality of life (QOL)6 monthsThe investigators will estimate the effect size of the intervention on youth-parent communication about quality of life by assessing quantitative changes in in general pediatric and Sickle Cell disease Quality of Life questionnaires administered to both parents and youths.
Effect size of the intervention on youth-parent communication about resource use6 monthsThe investigators will estimate the effect size of the intervention on youth-parent communication about resource use, such as urgent outpatient appointments, emergency room visits, hospitalizations, missed days from school and parent productivity by assessing quantitative changes in questionnaires administered to parents.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026